ID   UM-UC-1
AC   CVCL_2743
SY   UMUC1; University of Michigan-Urothelial Carcinoma-1
DR   BTO; BTO:0006457
DR   EFO; EFO_0006770
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473231
DR   BioSample; SAMN10988038
DR   cancercelllines; CVCL_2743
DR   CancerTools; 160436
DR   Cell_Model_Passport; SIDM01409
DR   Cosmic; 1927293
DR   Cosmic; 1938699
DR   Cosmic; 2700981
DR   DepMap; ACH-000834
DR   ECACC; 06080301
DR   EGA; EGAS00001000610
DR   GEO; GSM136249
DR   GEO; GSM888823
DR   GEO; GSM1574557
DR   LiGeA; CCLE_460
DR   PharmacoDB; UMUC1_1642_2019
DR   Progenetix; CVCL_2743
DR   Wikidata; Q54990970
RX   PubMed=3761468;
RX   PubMed=6471236;
RX   PubMed=16469639;
RX   PubMed=18812553;
RX   PubMed=19375735;
RX   PubMed=22460905;
RX   PubMed=23401075;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25997541;
RX   PubMed=26589293;
RX   PubMed=27270441;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://www.synapse.org/UC25
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Population: African American.
CC   Doubling time: 26 hours (PubMed=3761468).
CC   HLA typing: A*30:02,36:01; B*35:01,53:01; C*04:01,16:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 1102; BRD1; Simple; p.Gln340Ter (c.1018C>T); Zygosity=Heterozygous (PubMed=27270441).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=85.83%; Native American=0%; East Asian, North=2.25%; East Asian, South=0%; South Asian=0%; European, North=2.87%; European, South=9.04% (PubMed=30894373).
CC   Discontinued: ECACC; 06080301; true.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ECACC=06080301; PubMed=25877200; PubMed=27270441
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12,14
ST   D16S539: 9,11
ST   D18S51: 15
ST   D21S11: 28,29
ST   D3S1358: 17,18
ST   D5S818: 13
ST   D7S820: 8,11
ST   D8S1179: 12,14
ST   FGA: 22,24
ST   Penta D: 2.2
ST   Penta E: 7,17
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 14,15
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   26Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 32
//
RX   PubMed=3761468; DOI=10.1016/S0022-5347(17)45139-1;
RA   Grossman H.B., Wedemeyer G., Ren L.-Q., Wilson G.N., Cox B.;
RT   "Improved growth of human urothelial carcinoma cell cultures.";
RL   J. Urol. 136:953-959(1986).
//
RX   PubMed=6471236; DOI=10.1016/S0022-5347(17)49883-1;
RA   Grossman H.B., Wedemeyer G., Ren L.-Q.;
RT   "UM-UC-1 and UM-UC-2: characterization of two new human transitional
RT   cell carcinoma lines.";
RL   J. Urol. 132:834-837(1984).
//
RX   PubMed=16469639; DOI=10.1016/S0022-5347(05)00323-X;
RA   Sabichi A.L., Keyhani A., Tanaka N., Delacerda J., Lee I.-L., Zou C.-P.,
RA   Zhou J.-H., Benedict W.F., Grossman H.B.;
RT   "Characterization of a panel of cell lines derived from urothelial
RT   neoplasms: genetic alterations, growth in vivo and the relationship of
RT   adenoviral mediated gene transfer to coxsackie adenovirus receptor
RT   expression.";
RL   J. Urol. 175:1133-1137(2006).
//
RX   PubMed=18812553; DOI=10.1093/jnci/djn304; PMCID=PMC2720731;
RA   Park H.-S., Park W.S., Bondaruk J., Tanaka N., Katayama H., Lee S.,
RA   Spiess P.E., Steinberg J.R., Wang Z., Katz R.L., Dinney C.P.N.,
RA   Elias K.J., Lotan Y., Naeem R.C., Baggerly K., Sen S., Grossman H.B.,
RA   Czerniak B.;
RT   "Quantitation of Aurora kinase A gene copy number in urine sediments
RT   and bladder cancer detection.";
RL   J. Natl. Cancer Inst. 100:1401-1411(2008).
//
RX   PubMed=19375735; DOI=10.1016/j.juro.2009.01.108; PMCID=PMC2680455;
RA   Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.;
RT   "The use of short tandem repeat profiling to characterize human
RT   bladder cancer cell lines.";
RL   J. Urol. 181:2737-2748(2009).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3; PMCID=PMC4470036;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172; PMCID=PMC5140783;
RA   Nickerson M.L., Witte N., McGee Im K., Turan S., Owens C.R., Misner K.,
RA   Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//